Full video transcriptClick to expand
Auto-generated transcript of @justagirlwithcancer's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00It's 8.30 at night. I don't want to talk about the fit. I am... hold on.
- 0:06Wait, hold on. Can you see this?
- 0:08I'm going out of town next week and there is a rock and roll party and so I'm trying to...
- 0:20Anyways, anyways, I'm playing dress up in my closet.
- 0:24So I want to share something with you. I have been on a nestrosal and a strosal. I don't know.
- 0:30For two weeks now and that is the aroma taste inhibitor and because I am post-manopausal, which is so wild to me,
- 0:44I'm 48 years old. I had a hysterectomy two years ago because I had a ferritin level of three and
- 0:51basically almost died and so I'd have a hysterectomy. I did keep my ovaries,
- 0:57which was supposed to keep me from getting breast cancer.
- 1:01Jokes on me.
- 1:03Anyway, so I am on this aroma taste inhibitor called anastrosal
- 1:10that I have to take every day for the next five to ten years and when I tell you the anxiety that
- 1:17thinking about taking that pill or the tamoxifen, which if I was paring menopausal, it would have been tamoxifen,
- 1:23said to me like
- 1:25that was probably one of the scariest things and so I want to show you this little ritual that I do every day when I
- 1:33take my pill. So I bought this thing off of Amazon and it holds all of my
- 1:39medications and I forgot what this one was called when I wrote it.
- 1:43So one time a day it is the no cancer pill and so let me show you what I do when I take it because I am all about
- 1:52positive energy manifestation and so this is what I do.
- 1:56So I hold my pill and I say a prayer and I say
- 2:01Dear God and universe, I'm going to take this pill and this pill is only meant to stop my cancer
- 2:08from growing and to prevent future cancer. That is all it's allowed to do in my body.
- 2:14It's not allowed to do anything else except stop cancer from forming and
- 2:18prevent my current cancer from getting larger and I'm going to take it and that is all that it's allowed to do with my body.
- 2:28And then I take it and that's how we keep from getting side effects.
Anastrozole for breast cancer: what the evidence actually shows
Quick answer
The creator is a 48-year-old post-menopausal woman with hormone receptor-positive breast cancer who underwent a hysterectomy two years prior and retained her ovaries. She has been on anastrozole, a third-generation aromatase inhibitor, for approximately two weeks at the time of the video. Her clinical situation, post-menopausal status with ER-positive disease, is the standard indication for aromatase inhibitor therapy rather than tamoxifen.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Anastrozole for breast cancer: what the evidence actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Understanding weight gain at menopause
Background source for body-composition and weight-change discussions around menopause.
PubMed
Management of obesity in menopause
Current source for menopause-specific obesity management framing.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Anastrozole for breast cancer: what the evidence actually shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Anastrozole for breast cancer: what the evidence actually shows" from Courtney Benson. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is a 48-year-old post-menopausal woman with hormone receptor-positive breast cancer who underwent a hysterectomy two years prior and retained her ovaries.
The reason this review is not generic is the source wording and the canonical claim label "trt every night at 8 30 pm i take my anastrozole the little whit." In this clip, the useful excerpt is: "It's 8." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator is a 48-year-old post-menopausal woman with hormone receptor-positive breast cancer who underwent a hysterectomy two years prior and retained her ovaries.
FormBlends verdict
Testosterone evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is a 48-year-old post-menopausal woman with hormone receptor-positive breast cancer who underwent a hysterectomy two years prior and retained her ovaries. She has been on anastrozole, a third-generation aromatase inhibitor, for approximately two weeks at the time of the video. Her clinical situation, post-menopausal status with ER-positive disease, is the standard indication for aromatase inhibitor therapy rather than tamoxifen.
- Anastrozole reduces circulating estrogen by approximately 85-95% in post-menopausal women, and this estrogen suppression is the direct biological cause of its side effects, not expectation (Dowsett et al., 2005, Journal of Clinical Oncology).
- Roughly 35% of patients on aromatase inhibitors report arthralgia, and bone mineral density loss is a consistent finding that requires clinical monitoring regardless of coping practices (Goss et al., 2005, NEJM).
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Anastrozole reduces circulating estrogen by approximately 85-95% in post-menopausal women, and this estrogen suppression is the direct biological cause of its side effects, not expectation (Dowsett et al., 2005, Journal of Clinical Oncology).
- Roughly 35% of patients on aromatase inhibitors report arthralgia, and bone mineral density loss is a consistent finding that requires clinical monitoring regardless of coping practices (Goss et al., 2005, NEJM).
- Nocebo research shows negative expectations can amplify subjective side effect reporting, but this is different from spiritual rituals preventing pharmacological effects (Horing et al., 2019, Pain).
- Adherence to aromatase inhibitors drops significantly over time, and poor adherence is linked to worse survival outcomes, so anything that supports consistent pill-taking has real value (Hershman et al., 2011, Journal of Clinical Oncology).
- Weight-bearing exercise has shown evidence-based benefit for AI-associated joint pain and should be discussed with an oncologist as a first-line strategy (Irwin et al., 2015, Journal of Clinical Oncology).
- Tamoxifen versus aromatase inhibitor selection based on menopausal status is clinically accurate and reflects standard oncology practice.
- Patients using mindfulness or ritual practices around medication should still report all side effects to their care team, since symptoms like bone density loss require active clinical management, not reframing.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @justagirlwithcancer actually say?
She said she takes anastrozole nightly and uses a ritualized prayer to, as she put it, tell the pill it is "not allowed to do anything else except stop cancer from forming." Her explicit conclusion: "that's how we keep from getting side effects." She also mentioned being post-menopausal at 48 after a hysterectomy, keeping her ovaries as a supposed cancer-prevention measure, and experiencing significant anxiety about starting an aromatase inhibitor versus tamoxifen.
To be fair, she's sharing a coping ritual, not writing a clinical protocol. But the framing matters. When someone with 7,600 viewers states that a prayer-based intention practice is a mechanism for avoiding anastrozole side effects, that claim deserves scrutiny. She is not just saying "this helps my mindset." She is saying this is how side effects are prevented.
Does the science back this up?
No, not in the way she describes it. Anastrozole side effects are driven by estrogen suppression at the tissue level, and no published trial has shown that intention-setting or ritualized belief changes that pharmacology.
Anastrozole is a third-generation aromatase inhibitor that reduces circulating estrogen by roughly 85-95% in post-menopausal women (Dowsett et al., 2005, Journal of Clinical Oncology). The downstream consequences, including joint pain, hot flashes, and bone density loss, are a direct result of that estrogen depletion. They are not mediated by expectation or spiritual framing.
That said, there is legitimate science on placebo effects and nocebo effects in drug tolerance. A 2019 study by Horing et al. in the journal Pain demonstrated that negative expectations about side effects (the nocebo effect) can amplify symptom reporting. Reducing fear and catastrophizing around a medication may genuinely lower the subjective experience of some symptoms. But "lowering subjective distress" and "preventing side effects" are meaningfully different claims.
What did they get wrong (or right)?
She got the clinical distinction between tamoxifen and anastrozole mostly right. Tamoxifen is the standard choice for pre-menopausal women with hormone receptor-positive breast cancer, while aromatase inhibitors like anastrozole are used in post-menopausal women because their mechanism requires low baseline estrogen (Early Breast Cancer Trialists' Collaborative Group, 2015, Lancet). That part checks out.
What she got wrong is the causal claim about prayer and side effects. The line "that's how we keep from getting side effects" is not supported. Anastrozole's side effect profile is well-documented: roughly 35% of patients report arthralgia, and bone mineral density loss is a consistent finding (Goss et al., 2005, NEJM). These are biological events, not belief-responsive ones in any clinically meaningful way.
She also suggested that keeping her ovaries would protect against breast cancer. That is not a reliable protection. BRCA-related risk and hormone receptor-positive tumor biology are independent of ovarian preservation in this context.
What should you actually know?
Rituals and positive framing around medication are not harmful, and managing medication anxiety is a real clinical concern worth taking seriously. If a pill-labeling habit helps someone stay adherent to a five-to-ten-year medication regimen, that is genuinely valuable. Adherence to aromatase inhibitors drops significantly over time, and poor adherence is associated with worse outcomes (Hershman et al., 2011, Journal of Clinical Oncology).
But patients should not go into anastrozole treatment expecting that mindset will prevent side effects. If joint pain, bone loss, or other symptoms emerge, those need to be reported to an oncologist, not spiritually reframed. There are evidence-based interventions: weight-bearing exercise has shown benefit for AI-associated arthralgia (Irwin et al., 2015, Journal of Clinical Oncology), and bone density monitoring plus bisphosphonate therapy addresses skeletal effects.
- Tell your care team about side effects even if you have a coping ritual that helps.
- Anastrozole-associated joint pain affects a large proportion of users and has real management options.
- Emotional rituals can support adherence, but they do not replace clinical monitoring.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Courtney Benson · TikTok creator
7.6K views on this video
Every night at 8:30 PM, I take my anastrozole — the little white pill that’s part of my breast cancer treatment plan. Before I swallow it, I say the same prayer to God and the universe: keep my side effects light, my spirit strong, and my body healing. For anyone else on an aromatase inhibitor, I see you. We’re doing this one night, one dose, one prayer at a time. #Anastrozole #AromataseInhibitor #BreastCancerTreatment #HormonePositiveBreastCancer
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about anastrozole reduces circulating estrogen by approximately 85-95% in post-menopausal women,?
Anastrozole reduces circulating estrogen by approximately 85-95% in post-menopausal women, and this estrogen suppression is the direct biological cause of its side effects, not expectation (Dowsett et al., 2005, Journal of Clinical Oncology).
What does the video say about roughly 35% of patients on aromatase inhibitors report arthralgia,?
Roughly 35% of patients on aromatase inhibitors report arthralgia, and bone mineral density loss is a consistent finding that requires clinical monitoring regardless of coping practices (Goss et al., 2005, NEJM).
What does the video say about nocebo research shows negative expectations can amplify subjective side effect?
Nocebo research shows negative expectations can amplify subjective side effect reporting, but this is different from spiritual rituals preventing pharmacological effects (Horing et al., 2019, Pain).
What does the video say about adherence to aromatase inhibitors drops significantly over time,?
Adherence to aromatase inhibitors drops significantly over time, and poor adherence is linked to worse survival outcomes, so anything that supports consistent pill-taking has real value (Hershman et al., 2011, Journal of Clinical Oncology).
What does the video say about weight-bearing exercise has shown evidence-based benefit for ai-associated joint pain?
Weight-bearing exercise has shown evidence-based benefit for AI-associated joint pain and should be discussed with an oncologist as a first-line strategy (Irwin et al., 2015, Journal of Clinical Oncology).
What does the video say about tamoxifen versus aromatase inhibitor selection based on menopausal status?
Tamoxifen versus aromatase inhibitor selection based on menopausal status is clinically accurate and reflects standard oncology practice.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Courtney Benson, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.